cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2015-6-78-82cardiovascular-287Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMСТАТИНЫ ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК. СУЩЕСТВУЕТ ЛИ ПРЕПАРАТ ВЫБОРАSTATINS IN CHRONIC KIDNEY DISEASE. IS THERE A DRUG OF CHOICE?ДрапкинаО. М.DrapkinaO. M.

д.м.н., профессор, заместитель директора по научной и лечебной работе

КорнееваО. Н.KorneevaO. N.

к.м.н., главный врач

Тел.: +7 (925) 356-71-74 

doctorok@land.ruФГБУ “Государственный научно-исследовательский центр профилактической медицины” Минздрава России, МоскваNational Research Center for Preventive Medicine of the Ministry of Health, MoscowЛечебно-диагностический центр “Арт-Мед кардио”, МоскваDiagnostic and Treatment Center “Art -Med”, Moscow2015201220151467882Copyright © Драпкина О.М., Корнеева О.Н., 20152015Драпкина О.М., Корнеева О.Н.Drapkina O.M., Korneeva O.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/287

Хроническая болезнь почек (ХБП) ассоциирована с повышенным сердечно-сосудистым риском, и требует тщательного контроля дислипидемии. Терапия статинами признана целесообразной для профилактики и лечения сердечно-сосудистых заболеваний у пациентов с ХБП. Рассмотрены возможности применения статинов у таких пациентов, эффективность и безопасность их применения на различных стадиях ХБП, необходимость коррекции дозы, выбор конкретного статина. Проведен сравнительный анализ, обсуждены преимущества и недостатки применения розувастатина и аторвастатина при ХБП.

Chronic kidney disease (CKD) is related to increased cardiovascular risk, and requires thorough dyslipidemia control. Statin therapy is expedient for prevention and treatment of cardiovascular disorders in CKD patients. The opportunities are reviewed for the use of statins in these patients, efficacy and safety at different stages of CKD, the need for dosage correction and choice of the exact drug. The comparison performed, benefits and misconveniences discussed of rosuvastatin and atorvastatin in CKD. 

гиперлипидемияхроническая болезнь почексердечно-сосудистый рискаторвастатинрозувастатинскорость клубочковой фильтрацииhyperlipidemiachronic kidney diseasecardiovascular riskatorvastatinrosuvastatinglomerular filtration rateReferencesGansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382(9889): 339-52.Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382(9889): 339-52.Shvetsov MYu, Bobkova IN, Colin IB, Kamyshov ES. Current principles of diagnostics and treatment of chronic kidney disease: manual for doctors. Ed. Shilov EM, Saratov, 2011. Russian (Швецов М.Ю., Бобкова И. Н., Колина И.Б., Камышова Е. С. Современные принципы диагностики и лечения хронической болезни почек: методическое руководство для врачей. Под ред. Шилов Е.М. Саратов 2011).Shvetsov MYu, Bobkova IN, Colin IB, Kamyshov ES. Current principles of diagnostics and treatment of chronic kidney disease: manual for doctors. Ed. Shilov EM, Saratov, 2011. Russian (Швецов М.Ю., Бобкова И. Н., Колина И.Б., Камышова Е. С. Современные принципы диагностики и лечения хронической болезни почек: методическое руководство для врачей. Под ред. Шилов Е.М. Саратов 2011).Smirnov AV, Shilov EM, Dobronravov VA, et al. The national recommendations. Chronic kidney disease: basic principles of screening, diagnosis, prevention and treatment. 2012; 4-6. Russian (Смирнов А.В., Шилов Е.М., Добронравов В.А. и др. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. 2012; 4-6).Smirnov AV, Shilov EM, Dobronravov VA, et al. The national recommendations. Chronic kidney disease: basic principles of screening, diagnosis, prevention and treatment. 2012; 4-6. Russian (Смирнов А.В., Шилов Е.М., Добронравов В.А. и др. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. 2012; 4-6).Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis.2011; 217: 3-46.Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis.2011; 217: 3-46.Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003; 108(17): 2154-69.Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003; 108(17): 2154-69.Barsoum RS. Chronic kidney disease in the developing world. N Engl J Med 2006; 354(10): 997-9.Barsoum RS. Chronic kidney disease in the developing world. N Engl J Med 2006; 354(10): 997-9.Nikolic D, Nikfar S, Salari P, et al. Effects of statins on lipid profile in chronic kidney disease patients: a metaanalysis of randomized controlled trials. Curr Med Res Opin 2013; 29: 435-51.Nikolic D, Nikfar S, Salari P, et al. Effects of statins on lipid profile in chronic kidney disease patients: a metaanalysis of randomized controlled trials. Curr Med Res Opin 2013; 29: 435-51.Zhang X, Xiang С, Zhou Y, et al. Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials. BMC Cardiovascular Disorders 2014, 14:19.Zhang X, Xiang С, Zhou Y, et al. Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials. BMC Cardiovascular Disorders 2014, 14:19.Nikolic D, Banach M, Nikfar S, et al. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol 2013; 168: 5437-47.Nikolic D, Banach M, Nikfar S, et al. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol 2013; 168: 5437-47.Barylski M, Nikfar S, Mikhailidis DP, et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy — a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res 2013; 72: 35-44.Barylski M, Nikfar S, Mikhailidis DP, et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy — a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res 2013; 72: 35-44.Tonelli M, Wanner C, for the Kidney Disease Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global outcomes 2013 Clinical Practice Guideline. Ann Intern Med 2013.Tonelli M, Wanner C, for the Kidney Disease Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global outcomes 2013 Clinical Practice Guideline. Ann Intern Med 2013.Weiner MG, Xie D, Tannen RL. Replication of the Scandinavian Simvastatin Survival Study using a primary care medical record database prompted exploration of a new method to address unmeasured confounding. Pharmacoepidemiol Drug Saf 2008; 17(7): 661-70.Weiner MG, Xie D, Tannen RL. Replication of the Scandinavian Simvastatin Survival Study using a primary care medical record database prompted exploration of a new method to address unmeasured confounding. Pharmacoepidemiol Drug Saf 2008; 17(7): 661-70.Kolina I.B. Statins in chronic kidney disease: safety application. Effective pharmacotherapy. Urology and Nephrology. Special issue 2012: 16-21). Russian (Колина И.Б. Статины при хронической болезни почек: безопасность применения. Эффективная фармакотерапия. Урология и Нефрология. Спецвыпуск 2012: 16-21).Kolina I.B. Statins in chronic kidney disease: safety application. Effective pharmacotherapy. Urology and Nephrology. Special issue 2012: 16-21). Russian (Колина И.Б. Статины при хронической болезни почек: безопасность применения. Эффективная фармакотерапия. Урология и Нефрология. Спецвыпуск 2012: 16-21).Sukhija R, Bursac Z, Kakar P, et al. Effect of statins on the development of renal dysfunction. Am J Cardiol 2008; 101: 975-9.Sukhija R, Bursac Z, Kakar P, et al. Effect of statins on the development of renal dysfunction. Am J Cardiol 2008; 101: 975-9.Muntner P, He J, Astor BC, et al. Traditional and nontraditional risk factors predict сoronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16(2): 529-38.Muntner P, He J, Astor BC, et al. Traditional and nontraditional risk factors predict сoronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16(2): 529-38.Douglas K, O’Malley PG, Jackson JL. Meta-Analysis: The Effect of Statins on Albuminuria. Ann Intern Med 2006; 145: 117-24.Douglas K, O’Malley PG, Jackson JL. Meta-Analysis: The Effect of Statins on Albuminuria. Ann Intern Med 2006; 145: 117-24.Agarwal R. Statin induced proteinuria: renal injury or renoprotection? J Am Soc Nephrol 2004; 15(9): 2502-3.Agarwal R. Statin induced proteinuria: renal injury or renoprotection? J Am Soc Nephrol 2004; 15(9): 2502-3.Kasiske BL, Wanner C, O’Neill WCh. An Assessment of Statin Safety by Nephrologists. Am J Cardiol 2006; 97 (8A): 82С-5.Kasiske BL, Wanner C, O’Neill WCh. An Assessment of Statin Safety by Nephrologists. Am J Cardiol 2006; 97 (8A): 82С-5.European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012; 33: 1635-701.European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012; 33: 1635-701.Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, American Pharmacists Association, American Society for Preventive Cardiology, Association of Black Cardiologists, Preventive Cardiovascular Nurses Association, and Women Heart: The National Coalition for Women with Heart Disease. JACC 2013; 1-85.Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, American Pharmacists Association, American Society for Preventive Cardiology, Association of Black Cardiologists, Preventive Cardiovascular Nurses Association, and Women Heart: The National Coalition for Women with Heart Disease. JACC 2013; 1-85.Takenaka Т, Takane Н, Kikuta Т, et al. Statin Improves Flow-Mediated Vasodilation in Chronic Kidney Diseases. International J Hypertens 12/2013; 2013:876865. DOI:10.1155/2013/876865.Takenaka Т, Takane Н, Kikuta Т, et al. Statin Improves Flow-Mediated Vasodilation in Chronic Kidney Diseases. International J Hypertens 12/2013; 2013:876865. DOI:10.1155/2013/876865.National Institute for Health and Care Excellence Lipid modification July 2014. http:// www.nice.org.uk/Guidance/CG181.National Institute for Health and Care Excellence Lipid modification July 2014. http:// www.nice.org.uk/Guidance/CG181.

The authors declare that there are no conflicts of interest present.